欢迎来到天天文库
浏览记录
ID:55684256
大小:243.25 KB
页数:3页
时间:2020-05-24
《芳香化酶抑制剂治疗妇科内分泌疾病的效果分析.pdf》由会员上传分享,免费在线阅读,更多相关内容在行业资料-天天文库。
1、中国当代医药2014年9月第21卷第25期·药物与临床·芳香化酶抑制剂治疗妇科内分泌疾病的效果分析邓金凤南昌市第二医院妇产科.南昌330002【摘要】目的探讨芳香化酶抑制剂在妇科内分泌疾病治疗中的应用价值。方法选取2010年8月~2012年8月在本院治疗的妇科内分泌患者90例,分别给予依西美坦(n=36)、阿那曲唑(n=28)和来曲唑(n=26)治疗,观察芳香化酶抑制剂的疗效、3组患者血清雌二醇(E)抑制情况及不良反应发生情况。结果依西美坦组、阿那曲唑组和来曲唑组的治疗总有效率分别为94.44%、92.86%
2、和92.31%,差异无统计学意义(P>O.05)。治疗后3组患者血清E水平明显下降,与治疗前比较差异有统计学意义(P3、lysisofaromataseinhibitortreatmentofgynecologicendocrinediseasesDENGJin-fengDepartmentofObstetricsAndGynecology,theSecondHospitalofNanchangCity,Nanchang330002,China【Abstract】ObjectiveToexploretheapplicationvalueofaromataseinhibitoringynecologicendocrinedise4、ases.Meth-ods90patientswithgynecologicendocrinediseasestreatedinourhospitalfromAugust2010toAugust2012werese—lectedandrespectivelyforexemestane(n=36),anastrozole(n=28)andletrozole(n=26)treatment,thecurativeeffectofaromataseinhibitors,threegroupsofpatientswit5、hserumestradiolinhibitionconditionandadversereactionsoccurwereobserved.ResultsThetotaleffectiveratewas94.44%,92.86%and92.31%respectivelyinexemestanegroup,anastro-zolegroupandletrozolegroup,therewasnostatisticallysignificantdifferencefP>0.05).TheserumE2level6、inthreegroupsofpatientsweresignificantlydecreasedaftertreatment,thedifferencewasstatisticallysignificantcomparedwithbeforetreatmentCP<0.05).ThescramE2inhibitionrateandefficientinhibitioninexemestanegrouppatientswerebetterthantheothertwogroupsf户<0.05).Noseri7、ousadversereactionoccurredin3groups,onweightgainletrozolegroupwassignificantf尸≮0.05).ConclusionAromataseinhibitorscaneffectivelytreatgynecologicalendocrinediseases,anddrugtolerance.【Keywords】Aromataseinhibit0rs;Endocrinediseases;Serumestradio1;Applicationva8、lue妇科内分泌疾病极为常见,月经不调、痛经、子宫1资料与方法内膜异位等均属此病,一些乳腺疾病,如乳腺增生、乳1.1一般资料房胀痛、乳腺癌等也与内分泌失调相关;由于此病发选取2010年8月~2012年8月在本院接受治疗生范围广、发生易,导致众多女性患者饱受身心痛苦,的妇科内分泌患者90例,年龄21~52岁,平均(40.1±严重影响生活质量。第三代芳香化酶抑制剂(are.3.2)岁;其中乳腺癌38例(
3、lysisofaromataseinhibitortreatmentofgynecologicendocrinediseasesDENGJin-fengDepartmentofObstetricsAndGynecology,theSecondHospitalofNanchangCity,Nanchang330002,China【Abstract】ObjectiveToexploretheapplicationvalueofaromataseinhibitoringynecologicendocrinedise
4、ases.Meth-ods90patientswithgynecologicendocrinediseasestreatedinourhospitalfromAugust2010toAugust2012werese—lectedandrespectivelyforexemestane(n=36),anastrozole(n=28)andletrozole(n=26)treatment,thecurativeeffectofaromataseinhibitors,threegroupsofpatientswit
5、hserumestradiolinhibitionconditionandadversereactionsoccurwereobserved.ResultsThetotaleffectiveratewas94.44%,92.86%and92.31%respectivelyinexemestanegroup,anastro-zolegroupandletrozolegroup,therewasnostatisticallysignificantdifferencefP>0.05).TheserumE2level
6、inthreegroupsofpatientsweresignificantlydecreasedaftertreatment,thedifferencewasstatisticallysignificantcomparedwithbeforetreatmentCP<0.05).ThescramE2inhibitionrateandefficientinhibitioninexemestanegrouppatientswerebetterthantheothertwogroupsf户<0.05).Noseri
7、ousadversereactionoccurredin3groups,onweightgainletrozolegroupwassignificantf尸≮0.05).ConclusionAromataseinhibitorscaneffectivelytreatgynecologicalendocrinediseases,anddrugtolerance.【Keywords】Aromataseinhibit0rs;Endocrinediseases;Serumestradio1;Applicationva
8、lue妇科内分泌疾病极为常见,月经不调、痛经、子宫1资料与方法内膜异位等均属此病,一些乳腺疾病,如乳腺增生、乳1.1一般资料房胀痛、乳腺癌等也与内分泌失调相关;由于此病发选取2010年8月~2012年8月在本院接受治疗生范围广、发生易,导致众多女性患者饱受身心痛苦,的妇科内分泌患者90例,年龄21~52岁,平均(40.1±严重影响生活质量。第三代芳香化酶抑制剂(are.3.2)岁;其中乳腺癌38例(
此文档下载收益归作者所有